Interleukin-17A (IL-17A): A silent amplifier of COVID-19

One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can act...

Descripción completa

Detalles Bibliográficos
Autores principales: Maione, Francesco, Casillo, Gian Marco, Raucci, Federica, Salvatore, Cristian, Ambrosini, Giovanna, Costa, Luisa, Scarpa, Raffaele, Caso, Francesco, Bucci, Mariarosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318692/
https://www.ncbi.nlm.nih.gov/pubmed/34364043
http://dx.doi.org/10.1016/j.biopha.2021.111980
Descripción
Sumario:One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.

Ejemplares similares